Your browser doesn't support javascript.
loading
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Waldman, Boris; Ansquer, Jean-Claude; Sullivan, David R; Jenkins, Alicia J; McGill, Neil; Buizen, Luke; Davis, Timothy M E; Best, James D; Li, Liping; Feher, Michael D; Foucher, Christelle; Kesaniemi, Y Antero; Flack, Jeffrey; d'Emden, Michael C; Scott, Russell S; Hedley, John; Gebski, Val; Keech, Anthony C.
Afiliación
  • Waldman B; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Ansquer JC; Centre Hospitalier Universitaire de Dijon, Dijon, France; Clinsciences, Dijon, France.
  • Sullivan DR; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Department of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Jenkins AJ; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • McGill N; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
  • Buizen L; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Davis TME; School of Medicine, University of Western Australia, Fremantle, WA, Australia.
  • Best JD; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Imperial College London, London, UK.
  • Li L; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Feher MD; Lipid Clinic, Chelsea and Westminster Hospital Foundation Trust, London, UK; Department of Clinical and Experimental Medicine, University of Surrey, Surrey, UK.
  • Foucher C; Clinsciences, Dijon, France.
  • Kesaniemi YA; Oulu Medical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland.
  • Flack J; South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • d'Emden MC; Endocrine Research Unit, Royal Brisbane Hospital, Brisbane, QLD, Australia.
  • Scott RS; Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand.
  • Hedley J; Department of Internal Medicine, Wairau Hospital, Blenheim, New Zealand.
  • Gebski V; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Keech AC; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia. Electronic address: tony@ctc.usyd.edu.au.
Lancet Diabetes Endocrinol ; 6(4): 310-318, 2018 04.
Article en En | MEDLINE | ID: mdl-29496472
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenofibrato / Ácido Úrico / Diabetes Mellitus Tipo 2 / Gota / Hipolipemiantes Tipo de estudio: Clinical_trials / Etiology_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2018 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenofibrato / Ácido Úrico / Diabetes Mellitus Tipo 2 / Gota / Hipolipemiantes Tipo de estudio: Clinical_trials / Etiology_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2018 Tipo del documento: Article País de afiliación: Australia